FDAsafety guidance66% confidence
CDER Nitrosamine Impurity Acceptable Intake Limits
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Travere Therapeutics; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Nephrology · Drug
- Sub-indication
- General
Related signal: FDA Accepts Supplemental NDA for Travere's Filspari (Sparsentan)